Who we are
The Industry Pharmacogenomics Working Group (I-PWG) was established in 2000 and is comprised of functionally diverse members from pharmaceutical and biotechnology companies. Our diverse membership is made up of those engaging in regulatory, statistical, technological , genomic and biological research as well as operations. We engage pre-competitively to address emerging issues related to pharmacogenomics.
To improve patient care through integration of pharmacogenomics in drug development
- Impact the integration of pharmacogenomic research into global drug development and regulatory policy through sharing and promoting best practices
- Facilitate the use of genomic data to inform drug labels and clinical decision making
- Promote education of pharmacogenomic science